Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Sarepta (SRPT) to $182 from $196 and keeps an Overweight rating on the shares. The firm is inline with consensus on Q1 Elevidys sales, but expects a focus on launch trends post the recent safety update, the analyst tells investors in a preview heading into earnings for commercial small-to-mid cap biotechnology companies the analyst covers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta initiated with an Overweight at Wells Fargo
- Sarepta price target lowered to $112 from $150 at Guggenheim
- Sarepta price target lowered to $184 from $215 at Oppenheimer
- Positive Outlook for Sarepta Therapeutics Amid Favorable Trial Evaluations and Proactive Regulatory Response
- Sarepta announces EU regulators temporarily halted dosing of ELEVIDYS